Case Report

Further Evidence for Celiac Disease-associated Chorea?

Ruth H. Walker 1,2*

1 Departments of Neurology, James J. Peters Veterans Affairs Medical Center, Bronx, New York, 2 Mount Sinai School of Medicine, New York, United States of America

Abstract

Background: A number of neurological conditions have been reported to be associated with gluten sensitivity, including ataxia, peripheral neuropathy, epilepsy, and occasionally, chorea. The pathogenic role of anti-gliadin antibodies has been questioned, and pathophysiology remains controversial.

Case Report: I report chorea in a patient with celiac disease, which responded to a gluten-restricted diet. The response of the movement disorder to change in diet strongly suggests a functional role for anti-gliadin antibodies in the generation of chorea, probably involving basal ganglia targets.

Discussion: Gluten sensitivity may be a treatable cause of chorea.

Keywords: Chorea, celiac disease, anti-gliadin antibodies, gluten sensitivity
Citation: Walker RH. Further evidence for celiac disease-associated chorea? Tremor Other Hyperkinet Mov 2011;1: http://www.tremorjournal.org/article/view/32

* To whom correspondence should be addressed: E-mail: ruth.walker@mssm.edu

Introduction

Chorea has a large number of causes, including metabolic, structural, pharmacologic, genetic, and autoimmune factors. Despite extensive investigations, many patients remain undiagnosed. The onset of chorea in adulthood, without family history or associated features suggestive of a neurodegenerative process, such as dementia, seizures, or psychiatric disease, may limit the differential diagnoses to be considered. The presence of a medical comorbidity, particularly one associated with autoantibodies, may suggest the diagnosis.

Although still controversial, and challenging to prove, celiac disease has been reported to be associated with a number of neurologic conditions, 1,2 which are postulated to be due to the action of anti-gliadin antibodies upon neuronal targets.

Case Report

A 59-year-old Caucasian male was referred for evaluation of generalized chorea, which had been present for 1.5 years. All neurologic evaluations were performed by the author at the James J. Peters Veterans Affairs Medical Center. There was no relevant family history. As a child he had been diagnosed with celiac disease and underwent colonoscopy, but did not recall jejunoscopy. He followed a gluten-free diet as a child, which controlled his symptoms, but as an adult returned to a normal diet without problems. In recent months, he reported recurrence of abdominal pain and diarrhea. He has a long history of psychiatric disease with possible schizotypal personality disorder, depression, anxiety, and past alcohol dependence. He had received phenobarbital for “nerves” for a few months, but had never been hospitalized for psychiatric reasons.

Twelve years prior to evaluation he was treated with trazodone (100 mg/day) and sertraline (maximum dose unknown), which was switched to nefazodone (300 mg/day). Five years prior to presentation treatment was started with risperidone (1 mg/day), for paranoid ideation. For 3 years prior to neurological evaluation he was on stable doses of trazodone (100 mg/day), venlafaxine (375 mg/day) and mirtazapine (15 mg/day). Involuntary movements were first noted by his psychiatrist 1 year prior to referral. Six months prior to the current evaluation risperidone was switched to quetiapine 100 mg/day with no change in his involuntary movements. Doses of his antidepressants were unchanged. The movements remained unchanged when he was first seen by the author.
On examination he had generalized chorea with dystonic facial movements and right hand posturing (video segment 1). On the motor portion of the United Huntington’s Disease Rating Scale (UHDRS) he scored 9.

Laboratory evaluations including blood chemistry, peripheral blood smear, creatine kinase, liver enzymes, thyroid function tests, ceruloplasmin, and Huntington’s disease gene, were unremarkable. There was a mild microcytic anaemia, and ferritin was low, but no ferritin mutations were detected. Anti-gliadin antibodies were IgG = 139 U (normal range 0–20 U), IgA = 72 U (normal range 0–20 U).

Non-contrast brain MRI showed mild–moderate cerebral atrophy, microvascular changes in the periventricular white matter and pons, old hemorrhage in the posterior right subinsular region and a chronic infarct at the left frontoparietal junction.

Treatment was started with levetiracetam 500 mg twice a day with benefit, but then the potential role of celiac disease was recognized, and he was advised to adhere to a gluten-free diet. He stopped taking levetiracetam shortly thereafter. Three months later his involuntary movements were significantly reduced (video segment 2), scoring 2 on the UHDRS, and his gastrointestinal symptoms improved. Anti-gliadin antibodies showed IgG=15 U (normal range 0–9 U) and IgA=10 U (normal range 0–4 U). (Unfortunately, the laboratory had changed the reference values between the two tests. However, IgG decreased from 3.6 to 1.67 × the upper limit of normal (ULN), and IgA from 6.95 to 2.5 × ULN.)

**Discussion**

The main evidence suggesting celiac disease as the etiology of this patient’s chorea is the improvement seen with a gluten-restricted diet, supported by the reduction in anti-gliadin antibodies. Case reports of the benefit to neurological symptoms of a gluten-free diet are supported by the reduction in anti-gliadin antibodies. Case reports of quetiapine.

Patients with various neurological conditions may have anti-gliadin antibodies, but the significance of these, and whether they truly reflect a pathological autoimmune response and gluten sensitivity, remains unclear. Possibly, this patient’s chorea had an independent cause, and the response to his change in diet was coincidental. Of particular note, I cannot exclude a diagnosis of tardive dyskinesia due to risperidone. However, the distribution of the movements (affecting the trunk and face, but not the mouth or tongue) was atypical for this diagnosis, as was the improvement of symptoms while on a stable dose of quetiapine.

Although not conclusive, this case provides further evidence supporting celiac disease as a potentially reversible cause of chorea, especially in those who are non-adherent to a gluten-free diet. Detection of the presence of anti-gliadin antibodies is a useful mechanism for determining dietary compliance. Determination of gluten sensitivity should be considered in patients with chorea of undetermined etiology, particularly if there are concurrent gastrointestinal symptoms.

**Acknowledgments**

Thanks to the patient for his cooperation and to Patrick Chinnery, MD, for performing analysis of the ferritin light chain gene.

**References**

1. Hadjivassiliou M, Grunewald R, Sharrack B, et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. *Brain* 2003;126:685–691, http://dx.doi.org/10.1093/brain/awg050.
2. Pereira AC, Edwards MJ, Buttery PC, et al. Choreic syndrome and coeliac disease: a hitherto unrecognised association. *Mov Disord* 2004;19:478–482, http://dx.doi.org/10.1002/mds.10691.

3. Hadjivassiliou M, Davies-Jones GA, Sanders DS, et al. Dietary treatment of gluten ataxia. *J Neurol Neurosurg Psychiatry* 2003;74:1221–1224, http://dx.doi.org/10.1136/jnnp.74.9.1221.

4. Bhatia KP, Brown P, Gregory R, et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. *Brain* 1995;118:1087–1093, http://dx.doi.org/10.1093/brain/118.5.1087.

5. Hadjivassiliou M, Boscolo S, Davies-Jones GA, et al. The humoral response in the pathogenesis of gluten ataxia. *Neurology* 2002;58:1221–1226.

6. Abele M, Schols I, Schwartz S, et al. Prevalence of antigliadin antibodies in ataxia patients. *Neurology* 2003;60:1674–1675.

7. Bushara KO, Nance M, Gomez CM. Antigliadin antibodies in Huntington’s disease. *Neurology* 2004;62:132–133.